106 related articles for article (PubMed ID: 30220171)
1. [The impact of genetic variation of KDR on clinical outcomes of advanced colorectal cancer patients treated by first line bevacizumab based regimens].
Wang HX; Mei X; Gong TX; Han N; Liu P; Wang J; Zhang ZM
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2737-2742. PubMed ID: 30220171
[No Abstract] [Full Text] [Related]
2. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
[No Abstract] [Full Text] [Related]
3. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
[TBL] [Abstract][Full Text] [Related]
4. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
[No Abstract] [Full Text] [Related]
5. [The influence of Thymidine Phosphorylase genetic variation on clinical outcomes and safety of colorectal cancer patients received adjuvant chemotherapy after R0 resection].
Du YB; Zhang TF; Cui K; Jin SL; Xi Y; Ma W
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2569-2573. PubMed ID: 30220141
[No Abstract] [Full Text] [Related]
6. Influence of KDR Genetic Variation on the Effectiveness and Safety of Bevacizumab in the First-Line Treatment for Patients with Advanced Colorectal Cancer.
Wang F; Liu G
Int J Gen Med; 2022; 15():5651-5659. PubMed ID: 35734201
[TBL] [Abstract][Full Text] [Related]
7. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract][Full Text] [Related]
8. Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment.
Bai M; Li ZG; Ba Y
Int J Gen Med; 2021; 14():1041-1055. PubMed ID: 33790633
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the
Song ZZ; Zhao LF; Zuo J; Fan ZS; Wang L; Wang YD
Onco Targets Ther; 2020; 13():603-613. PubMed ID: 32021302
[TBL] [Abstract][Full Text] [Related]
10. [Clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy and the corresponding pharmacogenomics analysis].
Chen WC; Wu G; Zhang W; Zhu YZ; Zhou Y; Zhang H; Xia XB; Sun PC
Zhonghua Yi Xue Za Zhi; 2018 Nov; 98(42):3420-3425. PubMed ID: 30440137
[No Abstract] [Full Text] [Related]
11. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
12. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study.
Su J; Dai B; Yuan W; Wang G; Zhang Z; Li Z; Liu J; Song J
Cancer Chemother Pharmacol; 2020 May; 85(5):969-978. PubMed ID: 32314029
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the
Yan Z; Gu YY; Hu XD; Zhao Q; Kang HL; Wang M; Duan W; Guan Y
Oncol Lett; 2020 Sep; 20(3):3035-3045. PubMed ID: 32782621
[TBL] [Abstract][Full Text] [Related]
14. Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.
Sibertin-Blanc C; Mancini J; Fabre A; Lagarde A; Del Grande J; Levy N; Seitz JF; Olschwang S; Dahan L
Dig Liver Dis; 2015 Apr; 47(4):331-7. PubMed ID: 25617075
[TBL] [Abstract][Full Text] [Related]
15. Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer.
Sohn BS; Park SJ; Kim JE; Kim KP; Hong YS; Suh C; Kim YS; Kim SY; Im SA; Kim SY; Kim JH; Ahn JB; Park YS; Kim TW
Oncology; 2014; 87(5):280-92. PubMed ID: 25139485
[TBL] [Abstract][Full Text] [Related]
16. [Analysis on polymorphism at -509 C/T site of TGF-β1 gene in patients with keloids].
Song M; Liu Y
Zhonghua Shao Shang Za Zhi; 2014 Dec; 30(6):482-6. PubMed ID: 25608783
[TBL] [Abstract][Full Text] [Related]
17. NRP-1 and KDR polymorphisms are associated with survival time in patients with advanced gastric cancer.
Zhuo YJ; Shi Y; Wu T
Oncol Lett; 2019 Nov; 18(5):4629-4638. PubMed ID: 31611971
[TBL] [Abstract][Full Text] [Related]
18. Implication of KDR Polymorphism rs2071559 on Therapeutic Outcomes and Safety of Postoperative Patients with Gastric Cancer Who Received S-1-Based Adjuvant Chemotherapy: A Real-World Exploratory Study.
Meng L; Cao J; Kang L; Xu G; Yuan DW; Li K; Zhu K
Pharmgenomics Pers Med; 2023; 16():1027-1039. PubMed ID: 38046381
[TBL] [Abstract][Full Text] [Related]
19. Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study.
Han F; Tian H; Jin B; Chen G
Clin Med Insights Oncol; 2021; 15():11795549211059146. PubMed ID: 34924779
[TBL] [Abstract][Full Text] [Related]
20. Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans.
Jang MJ; Jeon YJ; Kim JW; Cho YK; Lee SK; Hwang SG; Oh D; Kim NK
Mol Carcinog; 2013 Nov; 52 Suppl 1():E60-9. PubMed ID: 23169005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
